Navigation Links
Novel breast screening technology increases diagnostic accuracy

OAK BROOK, Ill. The addition of three-dimensional breast imaginga technology called tomosynthesisto standard digital mammography significantly increases radiologists' diagnostic accuracy while reducing false positive recall rates, according to the results of a multi-center study published in Radiology.

"This is the first major advance in breast imaging and breast cancer screening since the development of breast MRI," said lead researcher Elizabeth A. Rafferty, M.D., director of Breast Imaging at the Avon Comprehensive Breast Center at Massachusetts General Hospital in Boston. "The beauty of tomosynthesis is that it addresses two major concerns with screening mammography: missed cancers and false positive rates."

According to the National Cancer Institute, there is convincing evidence that screening mammography reduces breast cancer mortality in women between the ages of 40 and 74. However, as many as 30 percent of breast cancers are not detected by mammography and an additional eight to 10 percent of women who undergo a screening mammogram are recalled for further testing when no cancer is present (called a false positive result).

Unlike a screening digital mammogram, which involves two X-ray images of each breast, breast tomosynthesis captures multiple, low-dose images from different angles around the breast. The images are then used to produce a three-dimensional reconstruction of the breast. Both digital mammography and breast tomosynthesis, which was approved by the United States Food and Drug Administration (FDA) in February of 2011, can be performed on the same mammography equipment in rapid succession.

Dr. Rafferty's study involved 1,192 women recruited from five sites, of whom 997, including 780 screening cases and 217 women who needed pre-biopsy breast imaging, had complete data sets. Each of the women underwent a standard digital mammogram followed by breast tomosynthesis. The total radiation dose for the combined procedure was less than 3 milligray, which is the FDA limit for a single mammogram.

Drawing from the eligible cases, the researchers then conducted two reader studies involving 312 and 310 cases, respectively. Twelve radiologists participated in the first reader study; 15 radiologists in the second. A total of 48 cancers were included in the first reader study; 51 cancers in the second.

Compared to digital mammography alone, the use of both standard mammogram and tomosynthesis resulted in increased diagnostic accuracy for all 27 radiologists. Additionally, the diagnostic sensitivity of the combined exam or the rate at which cancer present in the breast was correctly identified increased by 10.7 percent for radiologists in Reader Study 1 and 16 percent for radiologists in Reader Study 2.

"Almost all of the gains in diagnostic sensitivity with the combined modality were attributable to the improved detection and characterization of invasive cancers, which are the cancers we are most concerned about because of their potential to metastasize," Dr. Rafferty said.

With the addition of breast tomosynthesis to standard digital mammography, false positive recall rates also significantly decreased for all 27 of the radiologists. Absolute recall rate reductions of 38.6 percent and 17.1 percent were seen in Reader Studies 1 and 2, respectively.

"In the clinical setting, we would expect that type of reduction in recall rate to translate into a substantial number of unnecessary diagnostic tests being avoided," Dr. Rafferty said.


Contact: Linda Brooks
Radiological Society of North America

Related medicine news :

1. UNC, Vanderbilt discover a new live vaccine approach for SARS and novel coronaviruses
2. Moffitt Cancer Center researchers identify novel metabolic programs driving aggressive brain tumors
3. Novel treatment strategies for epilepsy
4. Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
5. Researchers ID potential patient population who may benefit from novel anti-platelet treatment
6. Undertreatment of common heart condition persists despite rapid adoption of novel therapies
7. Moffitt cancer center researchers find novel predictor for MDS progression risk
8. Novel surgery removes rare tumor, rebuilds face and jaw
9. Novel therapeutic targets identified for small cell lung cancer
10. Novel technique demonstrates interactions between malaria parasite and HIV
11. Genetic analyses reveal novel mutations as causes of startle disease
Post Your Comments:
(Date:11/29/2015)... (PRWEB) , ... November 30, 2015 , ... The Cyber Monday deal is a deep ... is the right time to get gifts for the skin care lover in your circle. ... filled with serums . This year, the 3 serums are staples: Collagen, Retinol and Hyaluronic ...
(Date:11/29/2015)... ... 29, 2015 , ... ProStatic Analog Distortion from Pixel Film ... for Final Cut Pro X. FCPX users can now apply distortion ... Destoying and creating chaotic distortion is now quick and simple, putting film makers ...
(Date:11/28/2015)... ... 2015 , ... Trying to relax on a couch can actually be uncomfortable, ... this design due to personal experience with a bad back," he said. , This ... as well as increases support. It also makes it easier to eat, do other ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published November ... and the University of British Columbia suggested that laws requiring bicyclists to wear helmets ... that part of the reason for the controversial conclusion is that, while helmets have ...
(Date:11/27/2015)... PITTSBURGH, PA (PRWEB) , ... November 27, 2015 ... ... of how filthy the toilets were," said an inventor from Hillside, N.J. "Many ... this improved seat cover so that individuals will always be protected from germs." ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 ) has ... of High Viscosity Drugs" report to their ... the addition of the "Self Administration of ... --> Research and Markets ( ... "Self Administration of High Viscosity Drugs" report ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Cell Surface Marker Testing ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/25/2015)... Calif. , Nov. 25, 2015  Amgen (NASDAQ: ... Biologics License Application (BLA) with the United ... for ABP 501, a biosimilar candidate to Humira ® ... adalimumab biosimilar application submitted to the FDA and represents ... Sean E. Harper , M.D., executive vice ...
Breaking Medicine Technology: